רספרים

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

SULPHAMETHOXAZOLE; TRIMETHOPRIM

Commercializzato da:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Codice ATC:

J01EE01

Forma farmaceutica:

תרחיף

Composizione:

SULPHAMETHOXAZOLE 200 MG / 5 ML; TRIMETHOPRIM 40 MG / 5 ML

Via di somministrazione:

פומי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Gruppo terapeutico:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Area terapeutica:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Indicazioni terapeutiche:

Treatment of urinary tract infections due to susceptible strains of the following organisms: - Escherichia coli - Klebsiella - Enterobacter - Proteus mirabilis - Proteus vulgaris - Proteus morganii. Treatment of acute otitis media in children due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. To date there are limited data available as to the safety of repeated use of Resprim in infants under 2 years of age. Resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. Treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei. Resprim is also indicated in the treatment of documented Pneumocystis carinii pneumonitis.

Data dell'autorizzazione:

2012-01-31